Skip to main content

The Next Big Thing in Biotech: Vivus

Adam Feuerstein, senior columnist for <I>TheStreet</I>, says Vivus is the next big thing in biotech.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.

Scroll to Continue

TheStreet Recommends